Sensitization of Human Renal Cell Carcinoma Cells to cis-Diamminedi-chloroplatinum(II) by Anti-Interleukin 6 Monoclonal Antibody or Anti-Interleukin 6 Receptor Monoclonal Antibody

Cancer Research

Volumn 55, Issue 3, 1995, Pages 590-596

  Mizutani, Youichi ^a   Bonavida, Benjamin ^b   Koishihara, Yasuo ^c   Akamatsu, Ken Ichi ^c   Ohsugi, Yoshiyuki ^c   Yoshida, Osamu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Chugai Phaumaceutical Co Ltd ^*  (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN RECEPTOR; MESSENGER RNA; MITOMYCIN C; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MH 166; MONOCLONAL ANTIBODY PM 1; RECEPTOR ANTIBODY; SUPEROXIDE DISMUTASE; TRANSPLATIN; UNCLASSIFIED DRUG; VINBLASTINE;

ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MULTIDRUG RESISTANCE; ONCOGENE C MYC; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; CELL LINE; CELL SURVIVAL; CISPLATIN; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; INTERLEUKIN-6; KIDNEY NEOPLASMS; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-6; RNA, NEOPLASM; TUMOR CELLS, CULTURED;

EID: 0028938688     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Yagoda, A. Chemotherapy of renal cell carcinoma: 1983–1989. Semin. Urol., 7: 199–206, 1989.
2. Yagoda, A., and Bander, N. H. Failure of cytotoxic chemotherapy, 1985–1988, and the emerging role of monoclonal antibodies for renal cancer. Urol. Int., 44: 338–345, 1989.
3. Hrushesky, W. J., and Murphy, G. P. Current status of therapy for advanced renal cell carcinoma. J. Surg. Oncol., 9: 277–288, 1977.
4. Harris, D. T. Hormonal therapy and chemotherapy for renal cell carcinoma. Semin. Oncol., 10: 422–430, 1983.
5. Kakehi, Y., Kanamaru, H., Yoshida, O., Nakanishi, S., Pastan, I., and Gottesman, M. M. Measurement of multidrug-resistance messenger RNA in urologicai cancers; elevated expression in renal cell carcinoma is associated with intrinsic drug resistance. J. Urol., 139: 862–864, 1988.
6. Kanamaru, H., Kakehi, Y., Yoshida, O., Nakanishi, S., Pastan, I., and Gottesman, M. M. MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor expiants. J. Natl. Cancer Inst., 81: 844–847, 1989.
7. Kishimoto, T. The biology of interleukin-6. Blood, 74: 1–10, 1989.
8. Gauldie, J., Richards, C., Harnish, C., Landsdorp, P., and Baumann, H. Interferon β2, B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc. Natl. Acad. Sci. USA, 84: 7251–7255, 1987.
9. Hirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y., Matsuda, T., Kashi-wamura, S., Nakajima, K., Koyama, K., Iwamatsu, A., Tsunasawa, S., Sakiyama, F., Matsui, H., Takahara, Y., Taniguchi, T., and Kishimoto, T. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature (Lond.), 324: 73–77, 1986.
10. Uyttenhove, C., Coulic, P. G., and Van snick, J. T. T cell growth and differentiation induced by interleukin MP1/IL6, the murine hybridoma/plasmacytoma growth factor. J. Exp. Med., 167: 1417–1422, 1988.
11. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwata, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, K., Kuramoto, A., and Kishimoto, T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (Lond.), 332: 83–87, 1988.
12. Miki, S., Iwano, M., Miki, Y., Yamamoto, M., Tang, B., Yokokawa, K., Sonoda, T., Hirano, T., and Kishimoto, T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett., 250: 607–610, 1989.
13. Takenawa, J., Kaneko, Y., Fukumoto, M., Fukatsu, A., Hirano, T., Fukuyama, H., Nakayama, H., Fujita, J., and Yoshida, O. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J. Natl. Cancer Inst., 83: 1668–1672, 1991.
14. Blay, J., Négrier, S., Combaret, V., Attali, S., Goillot, E., Merrouche, Y., Mercatello, A., Ravault, A., Tourani, J., Moskovchenko, J., Philip, T., and Favrot, M. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res., 52: 3317–3322, 1992.
15. Tsukamoto, T., Kumamoto, Y., Miyano, N., Matsumori, N., Takahashi, A., and Yanase, M. Interleukin-6 in renal cell carcinoma. J. Urol., 148: 1778–1782, 1992.
16. Kerr, J. F. R., Winterford, C. M., and Harmon, B. V. Apoptosis. Cancer (Phila.), 73: 2013–2026, 1994.
17. Sachs, L., and Lotem J. Control of programmed cell death in normal and leukemic cells; new implications for therapy. Blood, 82: 15–21, 1993.
18. Oyanagi, Y. Stimulatory effect of platinum(IV) ion on the production of superoxide radical from xanthine oxidase and macrophages. Biochem. Pharmacol., 26:473–476, 1977.
19. Nakano, H., Sugioka, K., and Nakano, M. Importance of Fe-ADP and relative unimportance of OH in the mechanism of mitomycin C induced lipid peroxidation. Biochim. Biophys. Acta, 796: 285–293, 1984.
20. Ono, M., Kohda, H., Kawaguchi, T., Ohhira, M., Sekiya, C., Namiki, M., Takeyasu, A., and Taniguchi, N. Induction of Mn-superoxide dimutase by tumor necrosis factor, interleukin-1 and interleukin-6 in human hepatoma cells. Biochem. Biophys. Res. Commun., 182: 1100–1107, 1992.
21. Dougall, W. C., and Nick, H. S. Manganese superoxide dimutase: a hepatic acute phase protein regulated by interleukin-6 and glucocorticoids. Endocrinology, 129: 2376–2384, 1991.
22. Fogh, J. Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors. Natl. Cancer Inst. Monogr., 49: 5–9, 1978.
23. Hay, R., Macy, M., Chen, T. R., McClintock, P., and Reid, Y. Cell lines and hybridomas. p. 156. New York: American Type Culture Collection, 1988.
24. Mizutani, Y., Nio, Y., and Yoshida, O. The streptococcal preparation OK-432 specifically augments the susceptibility of human urinary bladder tumor cells to the autologous peripheral blood lymphocytes. Cancer (Phila.), 69: 2999–3007, 1992.
25. Mizutani, Y., Nio, Y., Fukumoto, M., and Yoshida, O. Effects of Bacillus Calmette-Guérin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients urinary bladder cancer. Cancer (Phila.), 69: 537–545, 1992.
26. Hirata, Y., Taga, T., Hibi, M., Nakano, N., Hirano, T., and Kishimoto, T. Characterization of IL-6 receptor expression by monoclonal and polyclonal antibodies. J. Immunol., 143: 2900–2906, 1989.
27. Matsuda, T., Hirano, T., and Kishimoto, T. Establishment of an interleukin 6 (IL6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL6 monoclonal antibodies. Eur. J. Immunol., 18: 951–956, 1988.
28. Mizutani, Y., and Yoshida, O. Overcoming TNF-o resistance of human renal and ovarian carcinoma cells by combination treatment with buthionine sulfoximine and TNF-a. Role of TNF-a mRNA downregulation in tumor cell sensitization. Cancer (Phila.), 73: 730–737, 1994.
29. Mizutani, Y., and Bonavida, B. Overcoming CDDP resistance of human ovarian tumor cells by combination treatment with CDDP and TNF-a. Cancer (Phila.), 72: 809–818, 1993.
30. Daley-Tates, P. T., and McBrien, D. C. H. A study of the protective effect of chloride salts on cisplatin nephrotoxicity. Biochem. Pharmacol., 34: 2263–2369, 1985.
31. Riley, C. M., Sternson, L. A., and Repta, A. J. Assessment of cisplatin reactivity with peptides and proteins using reverse-phase high-performance liquid chromatography and flameless atomic absorption spectroscopy. Anal. Biochem., 124:167–179,1982.
32. Marunaka, T., Umeno, Y., Yoshida, K., Nagamachi, M., Minami, Y., and Fujii, S. High-pressure liquid chromatographic determination of ftorafur [ 1-(tetrahydro-2-furanyl)-5-fluorouracil] and GLC-mass spectrometric determination of 5-fluorouracil and uracil in biological materials after oral administration of uracil plus ftorafur. J. Pharm. Sei., 69: 209–213, 1980.
33. Sklar, M. D., and Prochownik, E. V.Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc. Cancer Res., 57: 2118–2123, 1991.
34. Mizutani, Y., Fukumoto, M., Bonavida, B., and Yoshida, O. Enhancement of sensitivity of urinary bladder tumor cells to cu-diamminedichloroplatinum(II) by c-myc antisense oligonucleotide. Cancer (Phila.), 75: 2546–2554, 1994.
35. Teicher, B. A., Holden, S. A., Kelly, M. J., Shea, T. C., Cucchi, C. A., Roswsky, A., Henner, W. D., and Frei, E., III. Characterization of a human squamous carcinoma cell line resistant to ct5-diamminedichloroplatinum(II). Cancer Res., 47: 388–393, 1987.
36. Nakagawa, K., Yokota, J., and Wada, M. Levels of glutathione 5-transferase it mRNA in human lung cancer cell lines correlative with the resistance to cisplatin and carboplatin. Jpn. J. Cancer Res., 79: 301–305, 1988.
37. Lotem, J., and Sachs, L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor βl and cancer chemotherapy compounds in myeloid leukemic cells. Blood, 50: 1750–1757, 1992.
38. Richon, V. M., Schulte, N., and Eastman, A. Multiple mechanisms of resistance to ci5-diamminedichloroplatinum(n) in murine leukemia L1210 cells. Cancer Res., 47: 2056–2061,1987.
39. Waud, W. R. Differential uptake of ds-diamminedichloroplatinum(II) by sensitive and resistant murine L1210 leukemia cells. Cancer Res., 47: 6549–6555, 1987.
40. Hromas, R. A., Andrews, P. A., Murphy, M. P., and Burns, C. P. Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells. Cancer Lett., 34: 9–13, 1987.
41. Andrews, P. A., Murphy, M. P., and Howell, S. B. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother. Pharmacol., 19: 149–154, 1988.
42. Taylor, D. M., Tew, K. D., and Jones, J. D. Effects of cis-dichlorodiammine platinum(II) on DNA synthesis in kidney and other tissues of normal and tumor-bearing rats. Eur. J. Cancer, 12: 249–254, 1976.
43. Roos, I. A. G., and Arnold, M. C. Interaction of an anti-tumor active platinum complex with DNA. J. Clin. Hematol. Oncol., 7: 374–388, 1977.
44. Pera, M. F., Rawlings, C. J., and Roberts, J. J. The role of DNA repair in the recovery of human cells from cisplatin toxicity. Chem.-Biol. Interact, 37: 245–261,1981.
45. Arrick, B. A., and Nathan, C. F. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res., 44: 4224–4232,1984.
46. Coleman, C. N., Glover, D. J., and Turrisi, A. T. Radiation and chemotherapy sensitizers and protectors. In: B. A. Chabner and J. M. Collins (eds.), Cancer Chemotherapy, pp. 424–448. Philadelphia: J. B. Lippincott Co., 1990.
47. Connors, T. A., Cleare, M. J., and Harrap, K. R. Structure activity relationships of the antitumor platinum coordination complexes. Cancer Treat. Rep., 63: 1499–1502, 1979.
48. Harrap, K. R., Jones, M., Wilkinson, C. R., Clink, H. M., Sparrow, S., Mitchley, B., Clarke, S., and Veasey, A. Antitumor, toxic, and biochemical properties of cisplatin and eight other platinum complexes. In: A. W. Prestayko, S. T. Cooke, and S. K. Carter (eds.), Cisplatin: Current Status and New Developments, pp. 193–212. New York: Academic Press, 1980.
49. Zwelling, L. A., Kohn, K. W., Ross, W. E., Ewig, R. A. G., and Anderson, T. Kinetics of formation and disappearance of a DNA cross-linking effect in mouse leukemia L1210 cells treated with cis- and fraw-diamminedichloroplatinum(II). Cancer Res., 38: 1762–1768, 1978.
50. Pascoe, J. M., and Roberts, J. J. Interactions between mammalian cell DNA and inorganic platinum compounds. Biochem. Pharmacol., 23: 1345–1357, 1974.
51. Evans, D. L., and Dive, C. Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res., 53: 2133–2139, 1993.
52. Rosselli, F., Sanceau, J., Wietzerbin, J., and Moustacchi, E. Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia. Hum. Genet, 89: 42–48, 1992.
53. Dusre, L., Raajgopalan, S., Eliot H. M., Covey, J. M., and Shinha, B. K. DNA intrastrand cross-link and free radical formation in a human multidrug-resistant cell line from mitomycin C and its analogues. Cancer Res., 50: 648–652, 1990.
54. Ohmori, T., Podack, E. R., Nishio, K., Takahashi, M., Miyahara, Y., Takeda, Y., Kubota, N., Funayama, Y., Ogasawara, H., and Ohira, H. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem. Biophys. Res. Commun., 792: 30–36, 1993.
55. Sato, K., Tuchiya, M., Saldanha, J., Koishihara, Y., Ohsugi, Y., Kishimoto, T., and Bendig, M. M. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res., 53: 851–856, 1993.